MRK - Compugen: Clinical Data Supports COM701 As A Potential Breakthrough Cancer Treatment

COM701 Exhibits Compelling Anti-Tumor Activity in Diverse, Challenging Patient Population

After languishing for the better part of five years, Compugen (CGEN) shares are up 140% YTD and more than 300% over the past 52 weeks. This recent price action is directly attributable to the first data read-outs on the company’s lead cancer immunotherapy program, COM701. The data showed that COM701 induced an anti-tumor response as a monotherapy and in combination settings (with Opdivo), across a diverse and challenging patient population, and in indications refractory to current PD-1 therapy.

It’s important to note by